interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Momelotinib Dihydrochloride

Generic competition · all medicines · read 12 November 2026

Is there a generic of Momelotinib Dihydrochloride, and who makes it?

Momelotinib Dihydrochloride appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Momelotinib Dihydrochloride1 dosage-form group in the Orange Book
0generic makers listed
  1. Momelotinib Dihydrochloride appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Ojjaara. No generic is listed as marketed.

2020202520302035204001brand 2023data datePatent 8486941 listed to expire 3 January 2035Patent 9809559 listed to expire 11 June 2035Patent RE48285 listed to expire 11 June 2035Patent 12576089 listed to expire 21 August 2039Patent 11963962 listed to expire 2 December 2040Exclusivity NCE to 15 September 2028Exclusivity ODE-441 to 15 September 2030
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 15 September 2028Exclusivity NCE Ojjaara
  • 15 September 2030Exclusivity ODE-441 Ojjaara
  • 3 January 2035Patent 8486941 drug substance
  • 11 June 2035Patent 9809559
  • 11 June 2035Patent RE48285 drug substance
  • 21 August 2039Patent 12576089
  • 2 December 2040Patent 11963962

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.